Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Cash Flow: 2014-2025

Historic Net Cash Flow for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $52.3 million.

  • Viridian Therapeutics, Inc.\DE's Net Cash Flow fell 43.53% to $52.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.7 million, marking a year-over-year decrease of 134.57%. This contributed to the annual value of -$3.2 million for FY2024, which is 93.87% up from last year.
  • Viridian Therapeutics, Inc.\DE's Net Cash Flow amounted to $52.3 million in Q3 2025, which was up 4,618.03% from $1.1 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Net Cash Flow high stood at $312.9 million for Q3 2022, and its period low was -$188.6 million during Q4 2022.
  • Its 3-year average for Net Cash Flow is $1.3 million, with a median of $1.1 million in 2025.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Net Cash Flow soared by 22,201.19% in 2021, and later plummeted by 2,032.60% in 2022.
  • Viridian Therapeutics, Inc.\DE's Net Cash Flow (Quarterly) stood at -$96.6 million in 2021, then plummeted by 95.32% to -$188.6 million in 2022, then surged by 95.35% to -$8.8 million in 2023, then tumbled by 1,048.49% to -$100.7 million in 2024, then tumbled by 43.53% to $52.3 million in 2025.
  • Its Net Cash Flow was $52.3 million in Q3 2025, compared to $1.1 million in Q2 2025 and $16.6 million in Q1 2025.